Development Management

Daniel Menard, Ph.D.

*** ***** ***** ****** . *******, WA 98198

514-***-**** . ************@***.***

Executive Profile

Accomplished professional with more than 15 years of experience in drug

discovery and early development with leading pharmaceutical and

biotechnology companies. Extensive background and hands-on research

experience in fields of pharmacology, toxicology, and neuropharmacology.

Skillfully direct all phases of drug discovery from identifying and

validating novel targets to preparing comprehensive IND-enabling

pharmacology packages. Disease area expertise includes CNS, PNS, CV,

oncology, infectious diseases, metabolic diseases and inflammatory

disorders.

Leadership profile includes positions as program leader, alliance

manager, and director of pre-clinical, multidisciplinary project teams.

Established and directed in vivo and in vitro pharmacology and toxicology

for multiple drug discovery programs; profiled compound's specificity and

selectivity and determined potential for adverse events, ADME, and PK/PD

in chronic disease models. Proven capabilities in budget/resource

management and in hiring, training, and retaining high-performing global

teams. Possess comprehensive knowledge of research/regulatory filings and

skilled in preparing IND documentation. Effective in managing external

relationships with CROs and other strategic partners; facilitate sharing

of best practices to continuously improve operations and spur substantial

and sustainable growth.

Core Competencies

Operations Management . P&L . Equipment Design . Lean/Six Sigma

Methodologies . IT/IS Administration

Candidate Drug Nomination . Follow-ups Selection . Proof of Concept . Data

Analysis . Staff Recruitment Training . Due Diligence . Strategic Planning

. In-licensing . Business Development . Marketing . HR

Site Management & Development . Alliance Management . Site Revenue &

Profitability

Professional Experience

LAB Research, Inc., Quebec, Canada . 2009-2010

President

Managed all scientific operations for 156,000 sq. ft facility offering GLP-

compliant, non-clinical development programs in support of IND and later-

stage regulatory submissions. Collaborated with clients and secured

company's reputation as leading developer of specialized models and non-

routine safety programs. Oversaw R&D activities; managed research

laboratories, toxicology operations, and pathology unit, as well as broad

range of business functions, including HR, finance/accounting, IT/IS, and

business development. Monitored QA activities and ensured compliance with

applicable regulatory standards and lab protocols. Held full P&L

responsibility.

Key achievements:

. Played key role in creating and updating company's strategic plan, as

well as all general business plans and R&D initiatives, to maximize

visibility, enhance competitive positioning, and protect interests.

. Established global HR strategy for 300+ employees. Managed, supported,

and evaluated team to stimulate professional development and maintain

continuous learning environment.

. Continuously assessed daily operations against core objectives;

documented and analyzed notable achievements and key milestones.

. Established operating structure and defined job profiles, specifically

for senior management positions.

. Appointed as central point of contact and primary spokesperson for key

clients.

. Delivered doubled sales target in December 2009; by end of February

2010, secured 50% of top line revenue target.

...Continued...

Daniel Menard, Ph.D. . Page 2 of 4 . ************@***.***

Professional Experience (Continued)

ALGOS Therapeutics, Inc., St.Paul, MN . 2007-2009

President / CEO, 2008-2009

President / CSO / COO, 2007-2008

Aggressively recruited to transition company's business model of

proprietary drug development to a mature CRO exclusively. Oversaw

scientific staff; trained, mentored, and supervised 25 research associates.

Monitored and allocated budget of $2.7M. Collaborated with Board of

Directors to define strategy and consulted with clients ensure highest

level of satisfaction. Evaluated existing operations and modified business

strategies to achieve key goals.

Key achievements:

. Streamlined operational processes to reduce redundancies; identified

new service offerings in order to position company for significant,

sustainable, and profitable growth.

. Directed facility improvements, such as doubling laboratory surface of

automated housing facility.

. In 2009, Algos Preclinical Services was recognized as "Best Place to

Work in the Twin Cities" and "Best Top 5 Emerging Company."

MDS Pharma Services, Bothell, WA . 2001-2006

Vice President/General Manager of Pharmacology & DM/PK, Early Stage

Development, 2004-2006

Promoted to oversee multiple satellite locations, including divisions in

DMPK and ADME in Montreal, Canada; screening, HTS custom assays, cellular

assays, and ion channels in Bothell, Washington; and pharmacology profiling

in Taipei, Taiwan. Managed global organization of 260 employees offering

thousands of assays and clinically relevant models. Collaborate with global

drug discovery organizations, including virtual companies, biotech

organizations, and leading pharma companies; at various stages of drug

development.

Key achievements:

. Generated $23M gross revenue during first year with company, despite

lack of structure within pharmacology unit.

. Instituted volume discounts in 2004 to improve service to clients and

drive top-line growth; proposed partnership between technical director

and business development director to support clients through all

phases of projects. Strategy contributed to company generating $27M

above plan.

. Led acquisition and integration of efficacy pharmacology project,

Skeletech, into core business units.

. Reorganized pharmacology unit to close Geneva site and launch

progressive lines of service in Bothell; evaluated viability of

facility in Taiwan. Exceeded revenue target by securing $35M in

revenue despite limited IT infrastructure and no marketing support.

. Successfully delivered $47M through business units by establishing

sound pharmacology infrastructure, including IT structure, new

business development strategies, and new lines of service.

. Redesigned pharmacology website to provide Japanese translation for

Japanese clients; efforts brought together Skeletech, Montreal, and

Bothell services, which had previously been in disarray.

Vice President of Pharmacology Operations, Early Stage Development, 2003-

2004

Directed all research activities and P&L to attain critical Pharmacology

objectives in alignment with overall company goals. Skillfully managed

daily global operations to maximize use of time and resources while meeting

budgetary controls. Conceptualized and launched innovative research

approaches and methods; continuously monitored quality of research and

guided colleagues on enhancing scientific portfolio and business

development efforts.

Key achievements:

. Collaborated with Drug Development team to facilitate new product

introductions and increase MDSPS's market presence.

. Secured business from 3 to 9 of top 10 large pharmaceutical companies.

...Continued...

Daniel Menard, Ph.D. . Page 3 of 4 . ************@***.***

Professional Experience (Continued)

Vice President of Pharmacology Operations, Early Stage Development, 2003-

2004

Key achievements (Continued)

. Provided strategic consultations and recommendations to both

scientific personnel and senior management at client companies;

interpreted data, recommended alternative uses of products/services,

and proposed technical solutions to improve effectiveness of sales

team.

. Recruited, supervised, and retained high performing teams of

professionals committed to individual and collective achievements.

Director of Pharmacology, Drug Discovery, Development, and Preclinical,

2002

Oversaw broad portfolio of pharmacology services and drove drug

development efforts; supervised and managed 10 directors. Established and

directed in vivo and ex vivo pharmacology for all drug discovery programs

across diverse disease areas, specifically CNS, PNS, CV, oncology,

infectious diseases, metabolic diseases, and inflammatory disorders.

Prioritized models and assays and established most critical for

development; determined dates for new model and assay introductions and

monitored project timelines.

Key achievements:

. Chaired product line development and target identification team;

served on new assays and biometrics team.

. Supported business development efforts in North American, European,

and Asian markets. Developed strategies to achieve significant growth

of pharmacology assay revenue. Doubled revenue from existing molecular

assays and brought in clients from road show. Secured considerable

business from new clients through consulting expertise, often as

participant, at client invitation, and in client project team

meetings.

. Recognized with Intelligence Client Service Award, 2002 and 2003 for

achieving 98% client satisfaction and 100% on time delivery of data.

Associate Director of Pharmacology, Drug Discovery, Development, and

Preclinical, 2001-2002

Provided comprehensive business development support for North American and

European operations; ensured strategic use of clinical pharmacological

principals and quantitative methods to support drug candidate development.

Served as Scientific Marketing Representative, promoting products to drive

revenues and secure competitive positioning for therapeutics. Oversaw

design and development of biological assays.

Key achievements:

. Appointed as leader of Xenogen technology project (oncology and

infectious diseases). Identified that investment, made before joining

MDSPS, was unprofitable and ended agreement, saving company

considerable amounts.

. Served as Scientific Marketing Representative, promoting products to

drive revenues and secure competitive positioning for therapeutics.

Led $500K investment in PatchExpress, used for Cardiac Safety

profiling, and generated additional $2M in revenue.

AstraZeneca R&D, Montreal, Canada . 1994-2001

Assistant Director of Pharmacology, 1997-2001

Directed in vivo Pharmacology programs and oversaw animal facility. Engaged

in all aspects of drug discovery, from lead identification to lead

optimization. Led pre-clinical and clinical projects teams, as well as

modeling group.

Key achievements:

. Appointed as team leader of General Pharmacology and Toxicology

therapy areas; served as active member of Candidate Drug nomination

Teams (CD to IND).

. Managed pre-project team, GPCR, and numerous exploratory projects.

. Led team that built behavioral pharmacology facility and developed

AZ's first candidate drug in record time.

. Represented management for individual and team performance.

...Continued...

Daniel Menard, Ph.D. . Page 4 of 4 . ************@***.***

Professional Experience (Continued)

Previous professional experience with Astra Pain Control and Astra Research

Centre Montreal (ARCM) includes Group Leader, In Vivo Pharmacology and

DM/PK Group, 1996-1997; Section Head, In Vivo Pharmacology and DM/PK Group,

1995 -1996; and Administrator/Negotiator, 1994-1995.

Additionally, served as Psychotherapist with St. Vincent de Paul Hospital,

Sherbrooke, 1987-1988.

Research Experience

Douglas Hospital Research Center & McGill University, Montreal, Canada .

1992-1994

Post-Doctoral Fellow, Neuropsychopharmacology Laboratory of Dr. R mi

Quirion

Queen's University Hospital, Department of Pharmacology & Toxicology,

Kingston, ON . 1992

Post-Doctoral Training, Laboratory of Dr. Khem Jhamandas

Education

Centre Hospitalier Universitaire Sherbrooke, Quebec, Canada . 1996

Ph.D. in Neuropharmacology, Department of Psychiatry & Pharmacology

. Supervisor: Dr. Francois Jolicoeur

Centre Hospitalier Universitaire Sherbrooke, Quebec Canada . 1992

Master of Science / Ph.D. in Pharmacology

. Supervisor: Dr. Francois Jolicoeur

. Served as Research Assistant to Dr. Jolicoeur in Psychiatry and

Pharmacology Department and Research Assistant to Dr. Bernard Belleau

Chemistry Department at Biochem-Pharma Montreal Canada

Universit de Sherbrooke Quebec, Canada . 1987

Bachelor of Science in Neuropsychology

Recent Continuing Medical Education & Additional Training

. Pain Education Day (3 MAINPRO-M1), University of Calgary

. Pain 2000 (14 MAINPRO-M1), University of Calgary

. Mechanisms of treatment of neuropathic pain, International Meetings

and Science, Inc., Washington

Additional training and professional development includes multiple

management courses through AstraZeneca; Leadership in Excellent Program

through MDS, Inc.; Executive Management Team Leadership Forum through MDS,

Inc.; Balanced Scorecard Implementation, and Lean Six Sigma methodologies

(Green Belt training).

Complete list of publications, as well as sample communications, available

upon request.

Contact this candidate